Related Experiment Video
Updated: May 2, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Reframing tricuspid regurgitation in Europe: from marker of risk to therapeutic target
Erwan Donal1, Prayuth Rasmeehirun1, Marina Petersen Saadi1
1University of Rennes, CHU Rennes, Inserm, LTSI-UMR 1099, Rennes F-35000, France.
Abstract:
Tricuspid regurgitation (TR), once considered a passive marker of advanced cardiac disease, is increasingly recognized as an independent contributor to morbidity, mortality, and healthcare burden. Recent evidence, including the pivotal TRILUMINATE trial and Tri-FR, together with supporting cost-effectiveness models, suggest that the correction of TR with T-TEER systems may improve patient outcomes and offer good value for money in European healthcare settings. This article explores the clinical rationale and economic imperative for considering TR as a modifiable and actionable target in modern cardiology ([Adamo M, Chioncel O, Pagnesi M, Bayes-Genis A, Abdelhamid M, Anker SD et al. Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. Eur J Heart Fail 2024;26:18-33.]).
Related Concept Videos
Mitral Regurgitation III: Medical Management
Aortic Regurgitation III: Medical Management
Aortic Regurgitation I: Introduction
Mitral Regurgitation I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests

